A study to assess the usefulness of fluciclovine (18F) PET/CT in patients with rising PSA after treatment of prostate cancer

Recruitment & Eligibility

Status: ot Recruiting

Sex: Not specified

Target Recruitment: 180

Inclusion Criteria

(1) The subject is a male =18 years old.
(2) The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with BCR on the basis of:
a. Post RRT / brachytherapy: Increase in PSA level =2.0 ng/mL above the nadir level after radiotherapy (RT) or brachytherapy (ASTRO-Phoenix criteria) [53], or
b. Post RP: EITHER two consecutive rises in PSA and final PSA >0.1ng/ml OR three consecutive rises in PSA., This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels).
i. In addition, the subject post RP, should have a PSA doubling time of =15 months OR PSA level =1.0 ng/mL at time of recruitment. The PSA doubling time will be calculated using the Memorial Sloan Kettering Cancer Center nomogram (http://www.mskcc.org/nomograms/prostate/psa-doubling-time), based on a minimum of two PSA levels within 12 months of screening, taken after the last recorded nadir PSA available at time of screening.
(3) The subject has not had previous recurrences of PCa, i.e. this is the first diagnosis of BCR.
(4) The subject is being considered for radical salvage therapy.
(5) The subject is able and willing to comply with study procedures, and signed, dated and timed informed consent is obtained before any study-related procedure is performed.
(6) The subject’s Eastern Cooperative Oncology Group [ECOG] performance status 0-2.
(7) The subject should not have received androgen-deprivation therapy within 3 months of screening.
(8) The subject has a normal or clinically acceptable medical history and vital signs findings at screening (up to 14 days before administration of study drug).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 45
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 135

Exclusion Criteria

(1) The subject has been previously included in this study.
(2) The subject has received, or is scheduled to receive, another investigational medicinal product (IMP) from 1 month before to 1 week after administration of fluciclovine (18F) injection.
(3) The subject has known hypersensitivity to fluciclovine (18F) injection or any of its constituents.
(4) The subject has had a choline PET/CT scan within 3 months of the screening visit.
(5) The subject has bilateral hip prostheses.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Boys and Girls

Phase 3

Tanaka Yoshiyuki

Updated 10/17/2023

Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine inJapanese Boys and Girls

Phase 1

Merck Sharp & Dohme LLC

Updated 2/19/2024

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 11/9/2020

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 7/5/2021

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 3/12/2024

Sisonke 4 (SHERPA)/ mRNA-1273-P508

Phase 3

Moderna Inc

Updated 3/4/2024

A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above.

Phase 1

GlaxoSmithKline Biologicals

Updated 8/21/2024

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 6/29/2020

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 12/12/2023

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Phase 1

Vertex Pharmaceuticals Incorporated

Updated 4/2/2024

A study to assess the usefulness of fluciclovine (18F) PET/CT in patients with rising PSA after treatment of prostate cancer

Recruitment & Eligibility

Study & Design

Related Trials

Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Boys and Girls

Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine inJapanese Boys and Girls

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Sisonke 4 (SHERPA)/ mRNA-1273-P508

A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above.

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).

Clinical Trial Alerts

Clinical Trial Alerts